Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BMS-813160 is the first dual CCR2/CCR5 antagonist to enter Clinical development for cardiovascular.
説明 | BMS-813160 is the first dual CCR2/CCR5 antagonist to enter Clinical development for cardiovascular. |
別名 | BMS 813160 |
分子量 | 484.64 |
分子式 | C25H40N8O2 |
CAS No. | 1286279-29-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (113.49 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BMS-813160 1286279-29-5 Immunology/Inflammation Microbiology/Virology CCR Inhibitor CC chemokine receptor dual antagonist BMS813160 peritonitis CD11b BMS 813160 inflammation CTX thioglycollate inhibit mouse oral inhibitor